Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antbody-drug conjugates - LigaChem Biosciences/Nordic Nanovector

Next Previous
Search
Drug Profile

Research programme: antbody-drug conjugates - LigaChem Biosciences/Nordic Nanovector

Alternative Names: anti-CD37 ADC - Nordic Nanovector; anti-CD37 antibody - Nordic Nanovector; LCB14 15XX - LigaChem Biosciences/Nordic Nanovector; NNV 019

Latest Information Update: 08 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LegoChem Biosciences; Nordic Nanovector
  • Developer Nordic Nanovector
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 28 Nov 2020 No recent reports of development identified for research development in Leukaemia in Norway (Parenteral)
  • 10 Oct 2016 Nordic NanoVector and LegoChem Biosciences enter a research collaboration for antibody-drug conjugates
  • 10 Oct 2016 Early research in Leukaemia in Norway (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top